Synthetic PPARγ agonists, which include rosiglitazone (Avandia) (Figure 1) [34, 35], troglitazone (Rezulin, withdrawn by the FDA due to causing liver failure) [36, 37], and pioglitazone (Actos; Takeda Pharmaceutical Ltd.)[38, 39], have provided insight into the therapeutic potential of PPARγ. The gene discussed is PPARG; the disease is Hepatic failure.